LONG-TERM FOLLOW UP OF ACUTE HEART FAILURE PATIENTS UNDERWENT LEVOSIMENDAN INFUSION: IDENTIFICATION OF RESPONDERS AND NON-RESPONDERS BY USING HLM CLASSIFICATION
Background Levosimendan (Levo) reduces mortality in Acute Heart Failure (AHF) that determines involvement of other organs beyond heart; similar to TNM used in oncology, we proposed HLM staging system to assess prognosis of HF patients evaluating heart damage (H), lung involvement (L) and malfunction...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2018-03, Vol.71 (11), p.A821-A821 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A821 |
|---|---|
| container_issue | 11 |
| container_start_page | A821 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 71 |
| creator | Alfarano, Maria Severino, Paolo Mancini, Ilaria Pucci, Mariateresa Pagliaroli, Elisa Straito, Martina Ferrari, Ilaria Peroni, Stefano Calcagno, Simone Fusto, Antonio Mancone, Massimo Fedele, Francesco |
| description | Background Levosimendan (Levo) reduces mortality in Acute Heart Failure (AHF) that determines involvement of other organs beyond heart; similar to TNM used in oncology, we proposed HLM staging system to assess prognosis of HF patients evaluating heart damage (H), lung involvement (L) and malfunction (M) of peripheral organs. The aim is to evaluate the outcomes of Levo infusion in AHF patients and identify the predictors of cardiac mortality and rehospitalization for major cardiovascular and cerebrovascular events (MACCE) by using HLM classification Methods All 300 AHF enrolled patients received 24h Levo iv infusion (0.05- 0.2 μg/kg/min, no bolus) in addition to standard therapy. |
| doi_str_mv | 10.1016/S0735-1097(18)31362-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2014428861</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109718313627</els_id><sourcerecordid>2014428861</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1301-fdabb81628747e6b0c604c1d5b43563841b2fadd8ae4cdf57d36a1078438329f3</originalsourceid><addsrcrecordid>eNqFkd1O3DAQha2qSN0Cj1DJUm_KRYonTmxvb6qw6-xG8tqr_BT1ysqPIwUVFhKoxNvwqHhZhLjjakbj852R5yD0DchPIMDOC8JpHACZ8x8gzihQFgb8E5pBHIuAxnP-Gc3eJF_Q12m6IoQwAfMZelJGr4JS5hucGqXMJa622KQ4WVSlxGuZ5CVOk0xVucTbpMykLgtc6aXML32Llfxjimwj9TLRONNpVWRG_8LZ0j9mabbwhNF7v1wWW7PHCpzoJdZGB-9GF3-xJ_UKr9UGL1RSFG_wCTrq63-TO32tx6hKZblYB8qsvEQFLVACQd_VTSOAhYJH3LGGtIxELXRxE9GYURFBE_Z114naRW3Xx7yjrAbCRUQFDec9PUbfD7634-7uwU339mr3MN74lTYkEEWhEAy8Kj6o2nE3TaPr7e04XNfjowVi92HYlzDs_tIWhH0Jw3LP_T5wzn_h_-BGO7WDu2ldN4yuvbfdbvjA4RloWIQ-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014428861</pqid></control><display><type>article</type><title>LONG-TERM FOLLOW UP OF ACUTE HEART FAILURE PATIENTS UNDERWENT LEVOSIMENDAN INFUSION: IDENTIFICATION OF RESPONDERS AND NON-RESPONDERS BY USING HLM CLASSIFICATION</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Alfarano, Maria ; Severino, Paolo ; Mancini, Ilaria ; Pucci, Mariateresa ; Pagliaroli, Elisa ; Straito, Martina ; Ferrari, Ilaria ; Peroni, Stefano ; Calcagno, Simone ; Fusto, Antonio ; Mancone, Massimo ; Fedele, Francesco</creator><creatorcontrib>Alfarano, Maria ; Severino, Paolo ; Mancini, Ilaria ; Pucci, Mariateresa ; Pagliaroli, Elisa ; Straito, Martina ; Ferrari, Ilaria ; Peroni, Stefano ; Calcagno, Simone ; Fusto, Antonio ; Mancone, Massimo ; Fedele, Francesco</creatorcontrib><description>Background Levosimendan (Levo) reduces mortality in Acute Heart Failure (AHF) that determines involvement of other organs beyond heart; similar to TNM used in oncology, we proposed HLM staging system to assess prognosis of HF patients evaluating heart damage (H), lung involvement (L) and malfunction (M) of peripheral organs. The aim is to evaluate the outcomes of Levo infusion in AHF patients and identify the predictors of cardiac mortality and rehospitalization for major cardiovascular and cerebrovascular events (MACCE) by using HLM classification Methods All 300 AHF enrolled patients received 24h Levo iv infusion (0.05- 0.2 μg/kg/min, no bolus) in addition to standard therapy.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/S0735-1097(18)31362-7</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Cardiology ; Cerebrovascular system ; Heart diseases ; Heart failure ; Mortality</subject><ispartof>Journal of the American College of Cardiology, 2018-03, Vol.71 (11), p.A821-A821</ispartof><rights>2018 American College of Cardiology Foundation</rights><rights>Copyright Elsevier Limited Mar 10, 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0735-1097(18)31362-7$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids></links><search><creatorcontrib>Alfarano, Maria</creatorcontrib><creatorcontrib>Severino, Paolo</creatorcontrib><creatorcontrib>Mancini, Ilaria</creatorcontrib><creatorcontrib>Pucci, Mariateresa</creatorcontrib><creatorcontrib>Pagliaroli, Elisa</creatorcontrib><creatorcontrib>Straito, Martina</creatorcontrib><creatorcontrib>Ferrari, Ilaria</creatorcontrib><creatorcontrib>Peroni, Stefano</creatorcontrib><creatorcontrib>Calcagno, Simone</creatorcontrib><creatorcontrib>Fusto, Antonio</creatorcontrib><creatorcontrib>Mancone, Massimo</creatorcontrib><creatorcontrib>Fedele, Francesco</creatorcontrib><title>LONG-TERM FOLLOW UP OF ACUTE HEART FAILURE PATIENTS UNDERWENT LEVOSIMENDAN INFUSION: IDENTIFICATION OF RESPONDERS AND NON-RESPONDERS BY USING HLM CLASSIFICATION</title><title>Journal of the American College of Cardiology</title><description>Background Levosimendan (Levo) reduces mortality in Acute Heart Failure (AHF) that determines involvement of other organs beyond heart; similar to TNM used in oncology, we proposed HLM staging system to assess prognosis of HF patients evaluating heart damage (H), lung involvement (L) and malfunction (M) of peripheral organs. The aim is to evaluate the outcomes of Levo infusion in AHF patients and identify the predictors of cardiac mortality and rehospitalization for major cardiovascular and cerebrovascular events (MACCE) by using HLM classification Methods All 300 AHF enrolled patients received 24h Levo iv infusion (0.05- 0.2 μg/kg/min, no bolus) in addition to standard therapy.</description><subject>Cardiology</subject><subject>Cerebrovascular system</subject><subject>Heart diseases</subject><subject>Heart failure</subject><subject>Mortality</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkd1O3DAQha2qSN0Cj1DJUm_KRYonTmxvb6qw6-xG8tqr_BT1ysqPIwUVFhKoxNvwqHhZhLjjakbj852R5yD0DchPIMDOC8JpHACZ8x8gzihQFgb8E5pBHIuAxnP-Gc3eJF_Q12m6IoQwAfMZelJGr4JS5hucGqXMJa622KQ4WVSlxGuZ5CVOk0xVucTbpMykLgtc6aXML32Llfxjimwj9TLRONNpVWRG_8LZ0j9mabbwhNF7v1wWW7PHCpzoJdZGB-9GF3-xJ_UKr9UGL1RSFG_wCTrq63-TO32tx6hKZblYB8qsvEQFLVACQd_VTSOAhYJH3LGGtIxELXRxE9GYURFBE_Z114naRW3Xx7yjrAbCRUQFDec9PUbfD7634-7uwU339mr3MN74lTYkEEWhEAy8Kj6o2nE3TaPr7e04XNfjowVi92HYlzDs_tIWhH0Jw3LP_T5wzn_h_-BGO7WDu2ldN4yuvbfdbvjA4RloWIQ-</recordid><startdate>20180310</startdate><enddate>20180310</enddate><creator>Alfarano, Maria</creator><creator>Severino, Paolo</creator><creator>Mancini, Ilaria</creator><creator>Pucci, Mariateresa</creator><creator>Pagliaroli, Elisa</creator><creator>Straito, Martina</creator><creator>Ferrari, Ilaria</creator><creator>Peroni, Stefano</creator><creator>Calcagno, Simone</creator><creator>Fusto, Antonio</creator><creator>Mancone, Massimo</creator><creator>Fedele, Francesco</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20180310</creationdate><title>LONG-TERM FOLLOW UP OF ACUTE HEART FAILURE PATIENTS UNDERWENT LEVOSIMENDAN INFUSION: IDENTIFICATION OF RESPONDERS AND NON-RESPONDERS BY USING HLM CLASSIFICATION</title><author>Alfarano, Maria ; Severino, Paolo ; Mancini, Ilaria ; Pucci, Mariateresa ; Pagliaroli, Elisa ; Straito, Martina ; Ferrari, Ilaria ; Peroni, Stefano ; Calcagno, Simone ; Fusto, Antonio ; Mancone, Massimo ; Fedele, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1301-fdabb81628747e6b0c604c1d5b43563841b2fadd8ae4cdf57d36a1078438329f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cardiology</topic><topic>Cerebrovascular system</topic><topic>Heart diseases</topic><topic>Heart failure</topic><topic>Mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alfarano, Maria</creatorcontrib><creatorcontrib>Severino, Paolo</creatorcontrib><creatorcontrib>Mancini, Ilaria</creatorcontrib><creatorcontrib>Pucci, Mariateresa</creatorcontrib><creatorcontrib>Pagliaroli, Elisa</creatorcontrib><creatorcontrib>Straito, Martina</creatorcontrib><creatorcontrib>Ferrari, Ilaria</creatorcontrib><creatorcontrib>Peroni, Stefano</creatorcontrib><creatorcontrib>Calcagno, Simone</creatorcontrib><creatorcontrib>Fusto, Antonio</creatorcontrib><creatorcontrib>Mancone, Massimo</creatorcontrib><creatorcontrib>Fedele, Francesco</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alfarano, Maria</au><au>Severino, Paolo</au><au>Mancini, Ilaria</au><au>Pucci, Mariateresa</au><au>Pagliaroli, Elisa</au><au>Straito, Martina</au><au>Ferrari, Ilaria</au><au>Peroni, Stefano</au><au>Calcagno, Simone</au><au>Fusto, Antonio</au><au>Mancone, Massimo</au><au>Fedele, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LONG-TERM FOLLOW UP OF ACUTE HEART FAILURE PATIENTS UNDERWENT LEVOSIMENDAN INFUSION: IDENTIFICATION OF RESPONDERS AND NON-RESPONDERS BY USING HLM CLASSIFICATION</atitle><jtitle>Journal of the American College of Cardiology</jtitle><date>2018-03-10</date><risdate>2018</risdate><volume>71</volume><issue>11</issue><spage>A821</spage><epage>A821</epage><pages>A821-A821</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>Background Levosimendan (Levo) reduces mortality in Acute Heart Failure (AHF) that determines involvement of other organs beyond heart; similar to TNM used in oncology, we proposed HLM staging system to assess prognosis of HF patients evaluating heart damage (H), lung involvement (L) and malfunction (M) of peripheral organs. The aim is to evaluate the outcomes of Levo infusion in AHF patients and identify the predictors of cardiac mortality and rehospitalization for major cardiovascular and cerebrovascular events (MACCE) by using HLM classification Methods All 300 AHF enrolled patients received 24h Levo iv infusion (0.05- 0.2 μg/kg/min, no bolus) in addition to standard therapy.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/S0735-1097(18)31362-7</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2018-03, Vol.71 (11), p.A821-A821 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_journals_2014428861 |
| source | Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Cardiology Cerebrovascular system Heart diseases Heart failure Mortality |
| title | LONG-TERM FOLLOW UP OF ACUTE HEART FAILURE PATIENTS UNDERWENT LEVOSIMENDAN INFUSION: IDENTIFICATION OF RESPONDERS AND NON-RESPONDERS BY USING HLM CLASSIFICATION |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T00%3A03%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LONG-TERM%20FOLLOW%20UP%20OF%20ACUTE%20HEART%20FAILURE%20PATIENTS%20UNDERWENT%20LEVOSIMENDAN%20INFUSION:%20IDENTIFICATION%20OF%20RESPONDERS%20AND%20NON-RESPONDERS%20BY%20USING%20HLM%20CLASSIFICATION&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Alfarano,%20Maria&rft.date=2018-03-10&rft.volume=71&rft.issue=11&rft.spage=A821&rft.epage=A821&rft.pages=A821-A821&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/S0735-1097(18)31362-7&rft_dat=%3Cproquest_cross%3E2014428861%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014428861&rft_id=info:pmid/&rft_els_id=S0735109718313627&rfr_iscdi=true |